Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SGN-STNV by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative...
SGN-STNV by Pfizer for Peritoneal Cancer: Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...
SGN-STNV by Pfizer for Gastric Cancer: Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
SGN-STNV by Pfizer for Pancreatic Cancer: Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
SGN-STNV by Pfizer for Cervical Cancer: Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
SGN-STNV by Pfizer for Colorectal Cancer: Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
SGN-STNV by Pfizer for Ovarian Cancer: Likelihood of Approval
SGN-STNV is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...